The evolving cannabis market has gained substantial popularity through the advocacy of prominent public figures. Cannabis used to be a taboo in most societies, however now, cannabis is becoming a topic that is publicly endorsed by millions. Notably, a handful of celebrities have brought the industry into the spotlight with their support as influential figures such as Seth Rogan, Snoop Dogg, Olivia Wilde, Jay Z, Danny DeVito, Wiz Khalifa, and Willie Nelson have all voiced their supportive opinions on the legalization of cannabis. Furthermore, certain celebrities have even launched their own cannabis-based brands for consumers to enjoy. For instance, Willie Nelson operates his own cannabis company called “Willie’s Reserve.” On his site, he sells a variety of products such as pre-rolled joints, dried flower, edibles, and oil concentrates. Moreover, Nelson has his own strain that was bred for him. The strain is named directly after him and causes uplifting and euphoric effects for its consumers. According to Wikileaf, many users have said they feel an increase in their creative spark and are filled with energy. Additionally, the strain is also popular among those looking to alleviate stress, anxiety, and depression. Furthermore, other consumers have utilized the strain to suppress nausea, glaucoma, migraines, and inflammation. The Willie Nelson strain is comprised of two Sativa strains, Vietnamese Black and Highland Nepalese. Generally, before the emergence of the legal cannabis market, many consumers had no idea where their supply came from. However, following the proliferation of legalization, vendors are required to disclose the seed-to-sale process of the plant to consumers. And overall the plant’s legalization is causing more consumers to avoid the black market and purchase their cannabis from a legal source instead. As a result, by 2024, the cannabis market is expected to reach USD 89.1 Billion from USD 14.5 Billion in 2018, according to Mordor Intelligence. Additionally, the market is expected to register a CAGR of 37% during the forecast period from 2019 to 2024. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Aphria Inc. (NYSE: APHA) (TSX: APHA), Organigram Holdings Inc. (NASDAQ: OGI) (TSX-V: OGI), Curaleaf Holdings, Inc. (OTC: CURLF) (CSE: CURA), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN)
Each year, more and more countries are moving towards approving cannabis use. In particular, medicinal cannabis is witnessing immense support as most of the countries looking to enter into the market space are more keen on the medical sector due to the therapeutic benefits associated with cannabis. However, several regions around the world have also either decriminalized or legalized the use of recreational cannabis in moderate amounts. For instance, Canada completely legalized adult-use cannabis in late 2018. On the other hand, countries such as Colombia and Spain have only decriminalized recreational use, allowing adults to possess up to a certain amount. Moreover, the U.S. has given states the jurisdiction to legalize cannabis or keep the drug illicit. As a result, more than half the U.S. legalized cannabis for medical use, while a fifth of the nation, including the District of Columbia, allows for legal recreational usage. While the medical marketplace is much more globally prevalent, the recreational market is expected to overshadow the medical segment as the North American market continues to mature. Additionally, as the recreational market continues to expand, consumers are also experiencing an influx of new products. Aside from traditional cannabis flower, consumers can now choose from a variety of products at dispensaries and retail stores. Now, cannabis-based concentrates, extracts, and edibles are becoming highly popular among consumers. Specifically, the edible and beverage marketplace is quickly gaining popularity due to the ease at which customers can use the products. Furthermore, a large recreational user base exists for the edible and beverage market, and the industry is heavily being accelerated by the increasing demand for wellness products to treat a variety of health concerns. According to data compiled by Reports and Data, the global cannabis-based beverage market was valued at USD 1.57 Billion in 2018. By 2026, the market is expected to reach USD 5.04 Billion while exhibiting a CAGR of 15.4% during the forecast period. BevCanna Enterprises Inc. (CSE: BEV), Anheuser-Busch InBev SA/NV (NYSE: BUD), Molson Coors Brewing Company (NYSE: TAP) (TSX: TPX), Brown-Forman Corporation (NYSE: BF-B), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN)
The cost of medical expenses can pile up very quickly for some. According to a survey conducted by Eventbrite, an average American spends approximately USD 199 each month on self-medication. In total, a typical American can spend upwards of USD 143,280 in their lifetime to treat themselves. Self-medicating is considered purchasing an over-the-counter (OTC) drug to treat a simple condition like headaches or a common cold. However, often times, medical attention is required for more severe cases. Certain therapies and treatments can cost thousands of dollars, potentially even hundreds of thousands depending on the severity of the condition. For instance, treatment of epilepsy (VNS therapy) in the U.S. can cost as much as USD 20,000, which includes implants and a surgical procedure. However, the cost of the surgery can vary throughout parts of the U.S. and can increase over time, according to the Epilepsy Foundation of Greater Chicago. Due to the rising costs of medical treatments, researchers and medical institutions have sought out alternatives to offer consumers cheaper options. Notably, cannabis has become a popular alternative within the healthcare marketplace, as specifically, CBD or cannabidiol is being leveraged across global markets because of its therapeutic benefits. Researchers have discovered that CBD can effectively be used to treat a variety of medical conditions, including cancer, arthritis, multiple sclerosis, and even epilepsy. Remarkably, the U.S. Food and Drug Administration approved the first-ever cannabis-based drug in 2018, Epidiolex, which is used to treat Dravet syndrome and Lennox-Gastaut syndrome, a form of epilepsy common among children. However, the FDA explicitly stated that more positive and large-scale clinical trials are required before the agency can approve more cannabis-based treatments. And as a result, scientists and researchers are now undergoing vigorous trials to uncover the efficacy of CBD. According to data compiled by Acumen Research and Consulting, the global cannabidiol market is projected to reach a market value of USD 22 Billion by 2026. Additionally, the market is expected to grow at a CAGR of 33% over the forecast period from 2019 to 2026. Pressure BioSciences, Inc. (OTC: PBIO), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), Sorrento Therapeutics, Inc. (NASDAQ: SRNE), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN)
FinancialBuzz.com News Commentary
Virtual Investor Conferences, in partnership with Grit Capital, today announced that the presentations from our recent virtual event are now available for on-demand viewing. Eight public & private company executives provided insight on innovation, consolidation, international expansion and specialization in millennial investment industries. Login to now to watch the presentations and hear answers to questions from the audience.
As of late 2018, it was legal to cultivate marijuana in the homes of 21 U.S. states and the District of Columbia. However, some states such as Rhode Island and Oklahoma strictly stated that home growers can only cultivate cannabis for medical purposes. On the other hand, states such as California and Colorado allow their residents to grow cannabis for both recreational and medical applications. In particular, Colorado allows its residents to grow up to six plants per person, but if a household has two or more people, it is limited to 12 plants maximum per householder. Before the prohibition era, many growers cultivated cannabis outdoors, largely for medicinal purposes. However, once former President Franklin D. Roosevelt signed the Marihuana Tax Act of 1937, a large influx of indoor and greenhouse facilities began to emerge. Therefore, cultivators were able to hide their grow houses from government officials. But now legalization has gained momentum across the world, resulting in more outdoor facilities once again. Indoor and greenhouse facilities are still popular, but outdoor facilities provide growers with a more natural end product. On the contrary, indoor and greenhouse facilities allow cultivators to control the growing environment, allowing them to manipulate the growing process of the plant and potentially grow more potent cannabis buds and obtain a substantially higher yield per harvest. Nowadays, greenhouse and outdoor facilities are much more popular because they’re built to produce on a large scale. However, the major drawback of these facilities is that the quality of the buds can be diminished as cultivators go for quantity over quality. Whether cultivators are choosing a more natural or a more controlled approach, it is still tapping into various consumer markets. For instance, a frequent consumer may prefer a more potent strain, while a first time user might be more attracted to the organic and natural aspect of outdoor-grown cannabis. Generally speaking, cultivators can market to different consumer trends based on their growing methods and techniques. According to data compiled by Grand View Research, the global legal marijuana market is expected to reach USD 146.4 Billion by 2025 while registering a CAGR of 34.6%. Canopy Rivers Inc. (OTC: CNPOF) (TSX-V: RIV), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Curaleaf Holdings, Inc. (OTC: CURLF) (CSE: CURA), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN)
In October 2018, Canada made history and became the second nation to legalize cannabis. Adding to the legislation’s significance is the fact that Canada enjoys the status of a G-7 nation. Furthermore, the remaining G-7 nations have all since adopted full or partial medicinal cannabis legislation, except for Japan. And since legalizing the plant, Canada has seen a large influx of new users willing to try it out. In the first quarter of 2019, Statistics Canada reported that about 5.3 million Canadians, or 18% of the population, 15 years and older reported using cannabis during the period. Remarkably, the estimated figure was 14% higher compared to the same period a year ago when recreational cannabis was still illegal. Among the reported consumers during the quarter, approximately 646,000 said they used cannabis for the very first time, nearly doubling year-over-year. The statistics suggest that first-time users are now more inclined to try cannabis due to its newfound legal status. Despite having access to sanctioned cannabis, an abundance of Canadians still receive their cannabis supply from a black market vendor. However, the number of Canadian dabbling in the black market has significantly fallen following legalization. During the quarter, it was reported that an estimated 47% of cannabis users, or 2.5 million Canadians, obtained their cannabis from legal sources such as dispensaries and retailers, which have more than doubled year-over-year. Government agencies have stressed the importance of purchasing cannabis from a credible and authorized source because the supply is generally much safer, as typically, most consumers who purchase on the black market have no idea where their supply came from and what it was treated with throughout the growing process. On the other hand, licensed cannabis operators are required to fully disclose the process from when it is first planted to when it is sold to the consumer, or seed-to-sale. As the legal market continues to mature throughout Canada, more and more users are expected to dive into the industry for the first time. And if Canada’s market continues to thrive and show positive results, other countries may be influenced and move towards legalization as well. According to data compiled by Verified Market Research, the global marijuana market was valued at USD 42.20 Billion in 2016. By 2025, the market is expected to reach USD 466.81 Billion while registering a CAGR of 35.3% from 2018 to 2025. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Aphria Inc. (NYSE: APHA) (TSX: APHA), The Green Organic Dutchman Holdings Ltd. (OTC: TGODF) (TSX: TGOD), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN)
Virtual Investor Conferences, in partnership with Grit Capital today announced the agenda for the upcoming Grit Capital Virtual lnvestor Conference. Individual investors, institutional investors, advisors, and analysts are invited to listen and watch live. The event will feature live video presentations by public & private companies, providing insight on innovation, consolidation, international expansion and specialization in millennial investment industries. The program opens at 1:00 PM ET on Wednesday, June 26th.
Marijuana has been classified as one of the most abused drugs in the entire world and despite its status as a controlled substance, it was highly accessible to consumers in regions around the globe. Marijuana is part of the cannabis family of plants and due to its psychoactive properties, it was virtually illegal in almost every country during the prohibition era. However, several countries have conducted clinical trials to better understand the efficacy of marijuana’s chemicals as well as the entire cannabis plant. Researchers concluded that cannabis can be leverage for its therapeutic benefits to treat a variety of medical conditions. In addition, certain regions around the world believe that cannabis can be an economic growth driver. And as a result, a select few regions have legalized or decriminalized the recreational use of cannabis. According to New Frontier Data, there were approximately 263 million cannabis users worldwide among ages 15 to 65 in 2018 and the North American region dominated the marketplace with the most consumers. The data also suggested that approximately 15.1% of the North American region had used cannabis during 2018 and on average, 6% of the global population had used cannabis during the year. The region boasts a higher cannabis user base compared to other areas because of its early adoption as North America’s cannabis legalization dates back to the 1990s when several U.S. states legalized medical cannabis. Now, more than half the U.S. has adopted medicinal cannabis legislation and some U.S. states have begun to legalize recreational cannabis after Colorado and Washington took the initial step in 2014. Then in 2018, Canada moved to fully legalize cannabis, following in Uruguay’s steps and becoming the second nation to ever do so. According to data compiled by GlobaInfoResearch, the global marijuana market is expected to reach USD 7.97 Billion in 2019. By 2024, the research suggests that marijuana is projected to exceed a value of USD 35.0 Billion while registering a CAGR 28%. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Molson Coors Brewing Company (NYSE: TAP) (TSX: TPX), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN), Sorrento Therapeutics, Inc. (NASDAQ: SRNE)
Cannabis’ mainstream appeal continues to grow, Wall Street has taken notice of the marijuana industry’s potential for quintupling, at minimum, in worldwide cannabis sales through 2029. Much of the increase in appeal is coming through the availability of cannabidiol (CBD) products, namely in the retail space. Major retailers and retail property owners are opening their doors to selling hemp-derived products from companies including Green Growth Brands (CSE:GGB) (OTC:GGBXF), Green Thumb Industries Inc. (OTC:GTBIF) (CSE:GTII), iAnthus Capital Holdings, Inc. (OTC:ITHUF) (CSE:IAN), Curaleaf Holdings, Inc. (OTC:CURLF) (CSE:CURA) and MedMen Enterprises Inc. (OTC:MMNFF) (CSE:MMEN).